Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonization) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.
1. An isolated human anti-ICOS antibody comprising a VH domain of an amino acid sequence of SEQ ID NO: 7, a VK domain of an amino acid sequence of SEQ ID NO: 2, and an engineered IgG1 Fc region, wherein the engineered IgG1 Fc region comprises complex N-glycoside-linked sugar chains in which fucose is not bound to N-acetylglucosamine in the reducing end of the sugar chain, wherein the antibody mediates enhanced ADCC activity as compared to the level of ADCC activity mediated by a parent antibody comprising the same VH and VK domains and a wild type Fc region, wherein said antibody depletes circulating ICOS-expressing T cells in vivo in a mammal for at least 14 days when administered as a single dose of 125 mg/m 2 .
2. A pharmaceutical composition comprising the antibody of claim 1 in a pharmaceutically acceptable carrier.
3. A method of treating an autoimmune disease or disorder in a human, comprising administering to a human in need thereof a therapeutically-effective amount of the antibody of claim 1 .
4. The method of claim 3 , wherein the autoimmune disease or disorder is SLE or scleroderma.
5. A method of treating or preventing rejection in a human transplant patient, comprising administering to a human in need thereof a therapeutically-effective amount of the antibody of claim 1 .
6. A method of depleting ICOS expressing T cells in a human patient comprising administering to a human in need thereof a therapeutically-effective amount of the antibody of claim 1 .
7. The method of claim 6 , wherein the depletion substantially persists for at least about 1, at least about 2, at least about 3 or at least about 4 weeks following the administration of the antibody.
8. The method of claim 6 , wherein at least about 95% of the T cells are depleted.
9. The method of claim 6 , wherein the ICOS expressing T cell is a memory T cell.
10. The method of claim 6 , wherein the ICOS expressing T cell is a circulating T cell.
11. A method of depleting circulating class switched B cells in a primate comprising administering an effective amount of the antibody of claim 1 .
12. The method of claim 11 , wherein the depletion substantially persists for at least about 1, at least about 2, at least about 3 or at least about 4 weeks following the administration of the antibody.
13. The method of claim 11 , wherein at least about 95% of the circulating class switched B cells are depleted.
14. An isolated anti-ICOS antibody comprising a VH domain of an amino acid sequence of SEQ ID NO: 7, a VK domain of an amino acid sequence of SEQ ID NO:2, and a modified IgG1 Fc region, wherein the antibody has complex N-glycoside-linked sugar chains bound to the modified IgG1 Fc region in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chain, wherein the antibody mediates enhanced ADCC activity as compared to the level of ADCC activity mediated by a parent antibody comprising the same VH and VK domains and a non-modified Fc region, and wherein said antibody depletes circulating ICOS-expressing T cells in vivo and depletes class switched B cells in a primate.
15. The antibody of claim 14 , wherein the primate is a non-human primate.
16. The antibody of claim 14 , wherein the primate is a human.
17. The antibody of claim 14 , wherein the depletion substantially persists for at least about 1, at least about 2, at least about 3 or at least about 4 weeks following the administration of the antibody.
18. The antibody of claim 14 , wherein at least about 95% of the circulating class switched B cells are depleted.
19. A method of treating a T cell malignancy in a human, comprising administering to a human in need thereof a therapeutically effective amount of the antibody of claim 1 .
20. An isolated anti-ICOS antibody comprising a VH domain of an amino acid sequence of SEQ ID NO: 7, a VK domain of an amino acid sequence of SEQ ID NO:2, and a variant IgG1 Fc region comprising complex N-glycoside-linked sugar chains in which fucose is not bound to N-acetylglucosamine in the reducing end of the sugar chain, wherein the antibody depletes circulating ICOS-expressing T cells in vivo.